Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 2 |
| Introduction | 8 | 1 |
| GBI Research Report Guidance | 8 | 1 |
| Endpoints - Clinical Trials in Dermatology - Overview | 9 | 1 |
| Endpoints Used for Regular Approval | 9 | 1 |
| Safety and Efficacy | 9 | 1 |
| Change in Inflammatory Lesion Counts | 9 | 1 |
| Varicella Zoster Virus (VZV) Antibody Response | 9 | 1 |
| Pain | 9 | 1 |
| Endpoints - Clinical Trials in Dermatology - Marketed and Pipeline Products Assessment | 10 | 80 |
| Alopecia | 10 | 1 |
| Primary Endpoints in Alopecia | 10 | 1 |
| Secondary Endpoints in Alopecia | 10 | 1 |
| Major Marketed Drugs - Safety and Efficacy Analysis | 11 | 1 |
| Propecia (finasteride) | 11 | 1 |
| Rogaine (minoxidil) | 12 | 1 |
| Kenalog-10 (triamcinolone acetonide) | 13 | 1 |
| Phase III Molecules Analysis | 14 | 1 |
| Phase III Primary Endpoint Analysis | 14 | 1 |
| Phase III Secondary Endpoint Analysis | 15 | 2 |
| Phase II Molecules Analysis | 17 | 1 |
| Phase II Primary Endpoint Analysis | 17 | 1 |
| Phase II Secondary Endpoint Analysis | 18 | 1 |
| Terminated Trials | 19 | 1 |
| Candidiasis | 19 | 1 |
| Primary Endpoints in Candidiasis | 19 | 1 |
| Secondary Endpoints in Candidiasis | 20 | 1 |
| Major Marketed Drugs (Azole Group) - Safety and Efficacy Analysis | 21 | 1 |
| Fluconazole | 21 | 1 |
| Itraconazole | 22 | 1 |
| Miconazole | 23 | 1 |
| Clotrimazole | 24 | 1 |
| Ketoconazole | 24 | 1 |
| Major Marketed Drugs (Echinocandins Class) - Safety and Efficacy Analysis | 25 | 1 |
| Anidulafungin | 25 | 1 |
| Micafungin | 26 | 1 |
| Major Marketed Drugs (Polyene class) - Safety and Efficacy Analysis | 27 | 1 |
| Nystatin | 27 | 1 |
| Phase III Molecules Analysis | 28 | 1 |
| Phase III Primary Endpoint Analysis | 28 | 1 |
| Phase III Secondary Endpoint Analysis | 29 | 3 |
| Most Promising Drugs Profiles | 32 | 1 |
| Voriconazole | 32 | 1 |
| Posaconazole | 33 | 1 |
| Phase II Molecules Analysis | 34 | 1 |
| Phase II Primary Endpoint Analysis | 34 | 1 |
| Phase II Secondary Endpoint Analysis | 34 | 2 |
| Terminated Trials | 36 | 1 |
| Atopic Dermatitis | 37 | 1 |
| Primary Endpoints in Atopic Dermatitis | 37 | 1 |
| Secondary Endpoints in Atopic Dermatitis | 37 | 1 |
| Major Marketed Drugs - Safety and Efficacy Analysis | 38 | 1 |
| Protopic | 38 | 1 |
| Elidel | 39 | 1 |
| MimyX | 40 | 1 |
| Atopiclair | 41 | 1 |
| Topical Corticosteroids | 41 | 1 |
| Phase III Molecules Analysis | 42 | 1 |
| Phase III Primary Endpoint Analysis | 42 | 1 |
| Phase III Secondary Endpoint Analysis | 43 | 4 |
| Most Promising Drugs Profiles | 47 | 1 |
| PH-10 | 47 | 1 |
| Phase II Molecules Analysis | 48 | 1 |
| Phase II Primary Endpoint Analysis | 48 | 2 |
| Phase II Secondary Endpoint Analysis | 50 | 4 |
| Terminated Trials | 54 | 1 |
| Herpes Zoster | 54 | 1 |
| Primary Endpoints in Herpes Zoster | 54 | 1 |
| Secondary Endpoints in Herpes Zoster | 55 | 1 |
| Major Marketed Drugs - Safety and Efficacy Analysis | 55 | 1 |
| Acyclovir (Zovirax) | 55 | 1 |
| Valacyclovir (Valtrex) | 56 | 1 |
| Famciclovir (Famvir) | 56 | 1 |
| Zostavax (Zoster Vaccine Live) | 57 | 1 |
| Phase III Molecules Analysis | 58 | 1 |
| Phase III Primary Endpoint Analysis | 58 | 2 |
| Phase III Secondary Endpoint Analysis | 60 | 2 |
| Most Promising Drugs Profiles | 62 | 1 |
| GSK1437173A | 62 | 1 |
| ASP2151 | 62 | 1 |
| FV-100 | 63 | 1 |
| Phase II Molecules Analysis | 64 | 1 |
| Phase II Primary Endpoint Analysis | 64 | 2 |
| Phase II Secondary Endpoint Analysis | 66 | 2 |
| Terminated Trials | 68 | 1 |
| Acne Vulgaris | 69 | 1 |
| Primary Endpoints in Acne Vulgaris | 69 | 1 |
| Secondary Endpoints in Acne Vulgaris | 70 | 1 |
| Major Marketed Drugs - Safety and Efficacy Analysis | 70 | 1 |
| Solodyn | 70 | 1 |
| Doryx | 71 | 1 |
| Epiduo | 72 | 1 |
| Duac | 73 | 1 |
| Tazorac | 73 | 1 |
| Ziana | 74 | 1 |
| Differin | 75 | 1 |
| Benzaclin | 76 | 1 |
| Phase III Molecules Analysis | 77 | 1 |
| Phase III Primary Endpoint Analysis | 77 | 2 |
| Phase III Secondary Endpoint Analysis | 79 | 4 |
| Most Promising Drugs Profiles | 83 | 1 |
| Clindamycin + Tretinoin | 83 | 1 |
| Phase II Molecules Analysis | 84 | 1 |
| Phase II Primary Endpoint Analysis | 84 | 2 |
| Phase II Secondary Endpoint Analysis | 86 | 3 |
| Terminated Trials | 89 | 1 |
| Endpoints - Clinical Trials in Dermatology - Company Profiles | 90 | 5 |
| Merck | 90 | 1 |
| Business Description | 90 | 1 |
| Product Portfolio | 90 | 1 |
| Propecia | 90 | 1 |
| Zostavax | 90 | 1 |
| Novartis | 91 | 1 |
| Business Description | 91 | 1 |
| Product Portfolio | 91 | 1 |
| Elidel | 91 | 1 |
| Famvir | 91 | 1 |
| GlaxoSmithKline | 92 | 1 |
| Business Description | 92 | 1 |
| Product Portfolio | 92 | 1 |
| Zovirax | 92 | 1 |
| Valtrex | 92 | 1 |
| Pfizer | 93 | 1 |
| Business Description | 93 | 1 |
| Product Portfolio | 93 | 1 |
| Diflucan | 93 | 1 |
| Eraxis | 93 | 1 |
| Astellas Pharma | 93 | 1 |
| Business Description | 93 | 1 |
| Product Portfolio | 94 | 1 |
| Mycamine | 94 | 1 |
| Protopic | 94 | 1 |
| Galderma | 94 | 1 |
| Business Description | 94 | 1 |
| Product Portfolio | 94 | 1 |
| Epiduo | 94 | 1 |
| Differin | 94 | 1 |
| Endpoints - Clinical Trials in Dermatology - Appendix | 95 | 5 |
| Market Definitions | 95 | 1 |
| Abbreviations | 95 | 2 |
| Research Methodology | 97 | 2 |
| Major Dermatological Disorders and their Product Profiling | 97 | 1 |
| Marketed and Pipeline Products Assessment | 98 | 1 |
| Company Profiles | 98 | 1 |
| Contact Us | 98 | 1 |
| Disclaimer | 99 | 1 |
| Sources | 99 | 1 |